Lu et al. [95] concluded through network analysis that CDK1, BCHE, ADH1A, ADH1C, EPHX2, and SRD5A2 were the core targets of CKI inhibiting liver cancer.It was discovered through in vitro research that CKI could effectively treat liver cancer by greatly inhibiting the proliferation of HepG5 cells, up-regulating ADH1A and SRD5A2, and down-regulating EPHX2 and CDK2. Here, ADH1A is linked to liver cancer.